A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...